scholarly journals Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Slavica Janeva ◽  
Toshima Z. Parris ◽  
Salmir Nasic ◽  
Shahin De Lara ◽  
Karolina Larsson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Treatment ◽  
Standardized Test ◽  
Her2 Status ◽  
Ki 67 ◽  
Surgical Specimen ◽  
Core Needle ◽  
Formalin Fixed Paraffin ◽  
Formalin Fixed Paraffin Embedded

Abstract Background Routine clinical management of breast cancer (BC) currently depends on surrogate subtypes according to estrogen- (ER) and progesterone (PR) receptor, Ki-67, and HER2-status. However, there has been growing demand for reduced immunohistochemistry (IHC) turnaround times. The Xpert® Breast Cancer STRAT4* Assay (STRAT4)*, a standardized test for ESR1/PGR/MKi67/ERBB2 mRNA biomarker assessment, takes less than 2 hours. Here, we compared the concordance between the STRAT4 and IHC/SISH, thereby evaluating the effect of method choice on surrogate subtype assessment and adjuvant treatment decisions. Methods In total, 100 formalin-fixed paraffin-embedded core needle biopsy (CNB) samples and matching surgical specimens for 98 patients with primary invasive BC were evaluated using the STRAT4 assay. The concordance between STRAT4 and IHC was calculated for individual markers for the CNB and surgical specimens. In addition, we investigated whether changes in surrogate BC subtyping based on the STRAT4 results would change adjuvant treatment recommendations. Results The overall percent agreement (OPA) between STRAT4 and IHC/SISH ranged between 76 and 99% for the different biomarkers. Concordance for all four biomarkers in the surgical specimens and CNBs was only 66 and 57%, respectively. In total, 74% of surgical specimens were concordant for subtype, regardless of the method used. IHC- and STRAT4-based subtyping for the surgical specimen were shown to be discordant for 25/98 patients and 18/25 patients would theoretically have been recommended a different adjuvant treatment, primarily receiving more chemotherapy and trastuzumab. Conclusions A comparison of data from IHC/in situ hybridization and STRAT4 demonstrated that subsequent changes in surrogate subtyping for the surgical specimen may theoretically result in more adjuvant treatment given, primarily with chemotherapy and trastuzumab.

The reliability of HER2-status determination from core-needle-biopsies and surgical specimens: A comparison of two established test methods (IHC, CISH)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22141-e22141
Author(s):  
V. Wolf ◽  
R. Groβe ◽  
J. Erggelet ◽  
H. J. Holzhausen ◽  
S. Hauptmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
In Situ Hybridisation ◽  
Test Method ◽  
Her2 Status ◽  
Surgical Specimen ◽  
Core Needle ◽  
Significant Difference ◽  
Her 2

e22141 Background: A milestone of breast-cancer therapy was the discovery of HER-2 entailing special targeted therapy with improved prognosis. The HER-2-status is routinely assessed through immunohistochemistry (IHC; HercepTest) showing protein over-expression and is double-checked with in-situ-hybridisation (ISH) demonstrating gene amplification in equivocal cases. It is questioned whether these methods achieve identical results in core-needle-biopsies and in excisional tumor specimens. Methods: We performed a retrospective comparative study in order to address these questions. From 01/03–06/08 we collected the HercepTest results from both core-needle-biopsy and surgical specimen of 109 breast cancer patients in our institute and compared these to newly evaluated chromogenic ISH (CISH) results for both specimen types in order to assess the reliability of HER-2- diagnosis of both methodological approaches and of specimen type. Results: We found no significant difference in the HER- 2-status determined from either needle-biopsies or surgical specimens irrespective of the test used. For the overall comparison (218 specimens) of HercepTest and CISH we found only slight, non-significant deviations. Four cases were CISH-negative in spite of HercepTest scoring of 3+. Vice versa, five out of the total of 38 (17.4%) CISH-positives did not correspond to the HercepTest results of 0 or 1+. Conclusions: Though not significant, there is some inconsistency in the HER-2-determination depending on the test-method, leaving these cases equivocal. In accordance with the literature, we therefore recommend to at least double-check samples with 2+ in the HercepTest as it is the current standard. Our data support the use of core-needle-biopsy as a reliable tissue sample for HER-2-diagnosis. [Table: see text]

M30 Expression Demonstrates Apoptotic Cells, Correlates With In Situ End-Labeling, and Is Associated With Ki-67 Expression in Large Intestinal Neoplasms

2000 ◽  
Vol 124 (12) ◽  
pp. 1768-1772 ◽  
Author(s):  
Norman John Carr
Keyword(s):  
Regression Line ◽  
Strong Positive Correlation ◽  
Strongly Correlated ◽  
Ki 67 ◽  
Formalin Fixed Paraffin ◽  
Formalin Fixed Paraffin Embedded ◽  
Secondary Objective ◽  
Formalin Fixed ◽  
Number Of Cells

Abstract Context.—The monoclonal antibody M30 recognizes a neoepitope of cytokeratin 18 produced during apoptosis. It is reactive in formalin-fixed, paraffin-embedded tissue and has great potential in the study of apoptosis in clinical and experimental material. Objectives.—To compare the results of M30 immunoexpression with a more established technique of demonstrating apoptosis in tissue sections, in situ end-labeling. A secondary objective was to compare the results with immunoexpression of the proliferation-associated antigen Ki-67. Design.—Retrospective analysis of adenomas and adenocarcinomas of the large intestine. Interventions.—Immunohistochemistry for M30 and Ki-67, and in situ end-labeling. Formalin-fixed, paraffin-embedded tissue was used. Main Outcome Measures.—The number of cells positive for M30, Ki-67, and in situ end-labeling, expressed as a proportion of the total number of cells counted. Results.—A strong positive correlation was found between in situ end-labeling and expression of M30, although the counts were widely scattered around the regression line. Counts of Ki-67 were strongly correlated with both M30 expression and in situ end-labeling. Immunoexpression of M30 was generally easier to interpret than in situ end-labeling, and the procedures for M30 immunohistochemistry were technically less exacting. Conclusion.—These findings support the application of M30 immunoreactivity in the study of apoptosis.

c-erbB-2 amplification in breast cancer: Detection in formalin-fixed, paraffin-embedded tissue by in situ hybridization☆

1994 ◽  
Vol 25 (4) ◽  
pp. 413-418 ◽  
Author(s):  
Karen L. Smith ◽  
Peter D. Robbins ◽  
Hugh J.S. Dawkins ◽  
John M. Papadimitriou ◽  
Sharon L. Redmond ◽  
...  
Keyword(s):  
Breast Cancer ◽  
In Situ Hybridization ◽  
Cancer Detection ◽  
Breast Cancer Detection ◽  
Formalin Fixed Paraffin ◽  
Formalin Fixed Paraffin Embedded ◽  
Formalin Fixed

Effect of neoadjuvant chemotherapy on oestrogen, progesterone, and HER-2 receptor expression in breast cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11588-e11588
Author(s):  
T. Sircar ◽  
S. Chaudhri ◽  
A. Francis
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Adjuvant Treatment ◽  
Core Biopsy ◽  
Locally Advanced ◽  
Receptor Expression ◽  
Her2 Status ◽  
Her2 Positive ◽  
Usual Practice ◽  
Surgical Specimen

e11588 Background: Neoadjuvant chemotherapy(NC) is used in treating locally advanced operable breast cancer. After surgery, further adjuvant treatment is offered based on the estrogen receptor (ER), progesterone receptor (PR) and HER2 status. Treatment post operatively can be based on the ER/PR/HER2 status of the core biopsy taken preoperatively. It is not a usual practice in the United Kingdom to repeat these markers on the surgical specimen. However a change in ER/PR or HER2 status following NC could have a profound effect on adjuvant treatment with the real possibility of appropriate therapy being unknowingly withheld. The aim of our study was to determine the percentage of patients whose ER/PR, HER2 receptor expression change with NC and if these changes lead to change in their adjuvant treatment. Methods: This is a retrospective study of 32 patients with locally advanced breast cancer who had NC followed by breast conservation surgery or mastectomy. Quick score (Q score) for ER/PR and the HER2 expression was measured both from the preoperative core biopsy and from the excision specimen following NC. Results: After NC, 5 patients had complete pathological response and 2 patients had residual ductal carcinoma in situ. 25(78%) patients had residual invasive malignancy. Quantitative change in Q scores for ER and PR was seen in 6 patients(24%) and 10 patients (40%) respectively. ER status changed from positive to negative in 1 patient(4%). PR status changed from positive to negative in 4 patients(16%) and from negative to positive in one patient (4%). One patient(4%) changed from HER2 negative to HER2 positive after NC. Conclusions: Change in 1 patient(4%) from HER2 negative to HER2 positive lead to change in adjuvant treatment who would have otherwise not received transzutumab.Q scores changed in 24% and 40% for ER and PR respectively, however, no change was observed with regards to hormonal adjuvant treatment. A study with a bigger cohort might address this issue. We suggest that ER/PR/HER2 status should routinely be checked in both core biopsy sample and also resection specimen. No significant financial relationships to disclose.

scholarly journals In Situ Proteomic Analysis of Glioblastoma Multiforme: A Translational Approach to Improve Prognostic/Diagnostic Routines

2020 ◽  
Vol 7 (29) ◽  
Author(s):  
Anally Menegasso ◽  
Marcel Pratavieira ◽  
Lucilene dos Santos ◽  
Flávio de Oliveira Lima ◽  
Marcelo Moraes ◽  
...  
Keyword(s):  
Proteomic Analysis ◽  
Laser Desorption Ionization ◽  
Ki 67 ◽  
Mass Spectral ◽  
Marker Proteins ◽  
Formalin Fixed Paraffin ◽  
Formalin Fixed Paraffin Embedded ◽  
Translational Approach ◽  
Formalin Fixed

In order to evaluate the use of matrix-assisted laser desorption ionization (MALDI) Mass Spectral Imaging (MSI) to Glioblastoma (GBM) studies, some sections of formalin fixed paraffin embedded samples of GBM tumors were submitted to classical immunoassays, to define the profile of distribution of some classical and well recognized molecular markers of GBM grade IV (Ki-67, S100, Glial GFAP, CD31 and CD34), while other sections of the same samples were submitted to in-tissue proteomic analysis by MALDI MSI, and both results compared to each other. The overlapping of the MALDI spectra obtained for the tryptic peptides with the immunohistochemical reactions of each marker protein were used to build a distribution map of the marker proteins all over the GBM tissue section. The results revealed a high correlation between both methods, indicating that MALDI MSI has enough sensitivity to be compared to the immunohistochemical methods, as well is sufficiently reliable to be used in biomarkers identification.

scholarly journals Evaluation of Ki-67 Index in Core Needle Biopsies and Matched Breast Cancer Surgical Specimens

2017 ◽  
Vol 142 (3) ◽  
pp. 364-368 ◽  
Author(s):  
Soomin Ahn ◽  
Junghye Lee ◽  
Min-Sun Cho ◽  
Sanghui Park ◽  
Sun Hee Sung
Keyword(s):  
Breast Cancer ◽  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Absolute Difference ◽  
Image Analyzer ◽  
Luminal A ◽  
Ki 67 ◽  
Surgical Specimen ◽  
Core Needle ◽  
Significant Difference

Context.— The Ki-67 index is strongly prognostic and is used as a surrogate marker to distinguish luminal A from luminal B breast cancer types. Objective.— To investigate differences in Ki-67 index between core needle biopsy samples and matched surgical samples in breast cancer. Design.— We included patients with invasive breast cancer who did not receive neoadjuvant therapy. A total of 89 pairs of core needle biopsies and surgical specimens were collected, and the Ki-67 index was assessed in hot spot areas using an image analyzer. We applied a 14% Ki-67 index to define low versus high groups. Results.— The Ki-67 index was significantly higher in core needle biopsies than in surgical specimens (P < .001), with a median absolute difference of 3.5%. When we applied 14% as a cutoff, 16 of 89 cases (18%) showed discrepancy. Thirteen cases showed a high Ki-67 index in core needle biopsies but a low Ki-67 index in surgical samples. There were 10 cases (11.2%) that showed discordant luminal A/B types between core needle biopsy and the matched surgical specimen. The reasons for the discordance were poor staining of MIB1 accompanied by fixation issues and intratumoral heterogeneity of the Ki-67 index. Conclusions.— A significant difference in the Ki-67 index between core biopsy and surgical specimens was observed. Our findings indicate that it may be better to perform the Ki-67 assay on the core needle biopsy and the surgical specimen than on only one sample.

Sign in / Sign up

Export Citation Format

Share Document